IMPACT OF TEBIPENEM-PIVOXIL ON THE INTESTINAL MICROBIOTA AND ON ESTABLISHMENT OF COLONIZATION WITH CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE IN MICE

Antimicrobial therapy has the potential to cause unintended adverse effects by promoting antibiotic-resistant bacteria. Therefore, as new antibiotics are developed there is a need to understand their potential to disrupt the indigenous microbiota of the colon and promote colonization by pathogens. Tebipenem pivoxil (Teb-piv), the first oral carbapenem, has potent in vitro activity against Enterobacterales pathogens, but requires combination with an appropriate β-lactamase inhibitor to achieve activity against Klebsiella pneumoniae carbapenemase and metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacterales抗菌治疗可通过促进耐药菌增殖引发非预期不良反应。因此，在研发新型抗生素时，亟需明确其对结肠土著微生物群的干扰潜力，以及是否会促进病原体定植。替比培南匹伏酯（Tebipenem pivoxil，缩写Teb-piv）是首款口服碳青霉烯类药物，对肠杆菌目（Enterobacterales）病原体具有强效体外抗菌活性，但需与合适的β-内酰胺酶抑制剂（β-lactamase inhibitor）联用，方可对产肺炎克雷伯菌碳青霉烯酶（Klebsiella pneumoniae carbapenemase）及产金属β-内酰胺酶（MBL）的碳青霉烯类耐药肠杆菌目（carbapenem-resistant Enterobacterales）发挥抗菌活性。